A study to compare the preference of two contrasting paracetamol formulations in the management of osteoarthritis pain
GlaxoSmithKline Consumer Healthcare
260 participants
Nov 1, 2007
Interventional
Conditions
Summary
Paracetamol is first-line pain management for osteoarthrits and this study is designed to investigate patient preference for sustained release paracetamol given 3xdaily compared with standard paracetamol tablet given 4xdaily.
Eligibility
Inclusion Criteria1
- At least 45 years of age, good general health, diagnosis of osteoarthritis of the knee with the pain worse in one knee, pain must be suitable for treatment with a simple analgesic
Exclusion Criteria1
- History of a secondard cause of osteoarthritis, medical condition that may affect the ability to rate pain, any contraindication to the use of paracetamol or ibuprofen, intra-articular steroid injection to the knees within the last 2 weeks
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All patients will receive both treatments. Two weeks treatment with immediate release paracetamol (1000mg four times daily - oral), and two weeks of extended release paracetamol (1330mg three times daily - oral). There is no washout period between the treatments.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12607000565448